Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536

Publisher： Karger

E-ISSN： 2296-5262|40|7-8|435-439

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.40, Iss.7-8, 2017-06, pp. : 435-439

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 976-982

John Wiley & Sons Inc

Access to resources Recommend Favorite

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3761-3768

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 1, 2017-01 ,pp. : 51-58

Bentham Science Publishers

Access to resources Recommend Favorite

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

By  

Oncology, Vol. 93, Iss. 1, 2017-04 ,pp. : 62-66

Karger

Access to resources Recommend Favorite

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite